top stories

Pfiz­er, Bris­tol My­ers dom­i­nate top 10 pre­dic­tions for the best-sell­ing drugs of 2022

3 hours ago
Pharma

A new can­cer im­munother­a­py brings cau­tious hope for a field long await­ing the next big break­through

8 hours ago
R&D
In Focus

CBO re­port high­lights ris­ing cost of brand-name drugs in Medicare as Con­gress con­sid­ers price ne­go­ti­a­tions

4 hours ago
Pharma

Latest

Most read

UP­DAT­ED: Pfiz­er fields a CRL for a $295M rare dis­ease play, giv­ing ri­val a big head start

Yesterday
R&D

Opin­ion: Flori­da is so mAb crazy, Ron De­San­tis wants to use mAbs that don't work

2 hours ago
R&D

Small biotechs with big drug am­bi­tions threat­en to up­end the tra­di­tion­al drug launch play­book

2 hours ago
In Focus
Marketing

Not cheap­er by the dozen: Bris­tol My­ers be­comes the 12th phar­ma com­pa­ny to re­strict 340B sales

3 hours ago
Pharma
see latest stream
People

Zymeworks re­places half its C-suite, aims to lay off 25% of to­tal work­force as new CEO takes over

5 days ago

GSK R&D chief Hal Bar­ron jumps ship to run a $3B biotech start­up, Tony Wood tapped to re­place him

6 days ago

Mar­tin Shkre­li re­ceives life­time in­dus­try ban, forced to re­turn al­most $65M in prof­its af­ter an­ti­com­pet­i­tive scheme

Last week
Financing

Gen 2: Berke­ley spin­out lands $175M megaround to keep it on the cut­ting edge of the boom­ing gene-edit­ing field

7 hours ago

Nasal sprays to stave off virus­es days at a time? J&J’s newest biotech part­ner draws $140M for 'proac­tive' ap­proach

8 hours ago

Eli Cas­din co-leads $250M in­fu­sion in­to mi­croflu­idics play­er that land­ed NIH fund­ing for Covid-19 test­ing

Yesterday
Startups

Or­biMed takes point on a new biotech launch, but al­most every­thing re­mains se­cret for now

5 days ago

A new start­up wants to take an­ti­sense and siR­NA one step fur­ther, and build more po­tent drugs than Io­n­is and Al­ny­lam

6 days ago

British bil­lion­aire Mike Platt hops on board a Lon­don start­up look­ing at drug dis­cov­ery from a dif­fer­ent an­gle

6 days ago
Deals

So what ex­act­ly does Ver­i­ly do? A new deal with L'Oréal does­n't clear up much

4 days ago

Faced with in­tense in­vestor back­lash, Unilever now says $68B is its fi­nal of­fer for GSK con­sumer health­care busi­ness

5 days ago

UCB buys its way to epilep­sy show­down with Jazz with $1.9B Zo­genix ac­qui­si­tion

6 days ago

Premium storiesSee all

'Al­tos was re­al­ly a once-in-a-life­time op­por­tu­ni­ty': Hal Bar­ron re­flects on his big move

5 days ago
Bioregnum
Cell/Gene Tx

FDA+ roundup: FDA's neu­ro­science deputy de­parts amid on­go­ing Aduhelm in­ves­ti­ga­tions; Califf on the ropes?

6 days ago
FDA+

An un­ortho­dox pro­pos­al for Bio­gen's Medicare-man­dat­ed Aduhelm tri­al

6 days ago
R&D
Pharma

What kind of biotech start­up wins a $3B syn­di­cate, woos a gallery of mar­quee sci­en­tists and re­cruits GSK's Hal Bar­ron ...

6 days ago
Deals
Cell/Gene Tx

Don't missSee all

New J&J CEO Joaquin Du­a­to promis­es an ag­gres­sive M&A hunt in quest to grow phar­ma sales

3 hours ago
Pharma

Mar­ket­ingRx roundup: Pfiz­er de­buts Pre­vnar 20 TV ads; Lil­ly gets first FDA 2022 pro­mo slap down let­ter

3 hours ago
Pharma
Marketing

As push to dis­rupt PD-(L)1 pric­ing heats up, Check­point trum­pets a piv­otal suc­cess

5 hours ago
R&D

Sur­prise piv­ot rocks eF­FEC­TOR's I/O plans — al­though ex­ecs promise big­ger slice of the NSCLC mar­ket in the long run

8 hours ago
R&D

Endpoints Standouts

Spe­cial re­port: Meet 20 ex­tra­or­di­nary women who are su­per­charg­ing bio­phar­ma R&D

Last month
People
Special

How Chi­na turned the ta­bles on bio­phar­ma's glob­al deal­mak­ing

3 months ago
China
In Focus

Con­tract re­search is hav­ing a mo­ment right now. Will M&A splash­es dri­ve the in­dus­try to even greater heights?

3 months ago
Outsourcing
In Focus

The coro­n­avirus vac­cine that the world for­got could still help save it

4 months ago
Coronavirus
In Focus

Peer review See all

Jan
21

As Hal Bar­ron steals the show, there’s no off po­si­tion on the John Maraganore switch; Dan­ny Bar-Zo­har makes an­oth­er ...

Jan
14

Er­ic Os­tertag reach­ing the end of the line as Po­sei­da chief, will be­come ex­ec­u­tive chair­man; Alec­tor ex­ec named CEO ...

Jan
7

How fam­i­ly and sci­ence moved Ex­elix­is' new CMO to work on on­col­o­gy block­busters; While John Maraganore racks up the ...

Dec
23

Joan Shen ends the year by say­ing good­bye to I-Mab; CRISPR Ther­a­peu­tics puts coal in R&D chief's stock­ing

Dec
17

Sara Kenkare-Mi­tra leaves Genen­tech for a chance to lead neu­ro R&D; Glax­o­SmithK­line alum jumps to Vi­for Phar­ma with ...

Pharma channel feed

5 days ago

Eu­ro­pean Par­lia­ment signs off on strength­en­ing drug reg­u­la­tor's abil­i­ty to tack­le short­ages

The Eu­ro­pean Par­lia­ment on Thurs­day en­dorsed a plan to in­crease the pow­ers of the Eu­ro­pean Med­i­cines Agency, which will be bet­ter equipped to mon­i­tor and mit­i­gate short­ages of drugs and ...

READ MORE

Sec­ondary patents prove to be key in biosim­i­lar block­ing strate­gies, re­searchers find

6 days ago

Backed by Bay­er's Leaps, Boston-based Celli­no lands $80M for cell ther­a­py-in-box

6 hours ago
Manufacturing
latest in Pharma

How much? Pfiz­er leads top phar­ma com­pa­nies' ramped up lob­by spend­ing on Con­gress

Yesterday

GSK looks to stand out in the se­vere asth­ma space with at-home in­jec­tions for kids 6 to 11 years old

Yesterday

A new non­prof­it wants to de­sign cheap drug tri­als, aim­ing to build on mas­sive­ly suc­cess­ful Covid-19 study

Yesterday

Fail­ing to con­firm clin­i­cal ben­e­fit, Gilead pulls 2 ac­cel­er­at­ed ap­proval in­di­ca­tions for can­cer drug

4 days ago
FDA+

An­oth­er day, an­oth­er xeno­trans­plant, as Unit­ed Ther­a­peu­tics looks to beat com­peti­tors to sci-fi-es­que break­through

4 days ago
see latest stories

Marketing channel feed

3 hours ago

Am­gen’s #Dear­Asth­ma spon­sored tweet lands big on game day, spark­ing thou­sands to re­spond

Am­gen want­ed to know how peo­ple with asth­ma re­al­ly felt about dai­ly life with the dis­ease. So it bought a pro­mot­ed tweet on Twit­ter not­ing the not-so-sim­ple re­al­i­ties of life with asth­ma ...

READ MORE

Crit­ics push back on Alzheimer’s As­so­ci­a­tion ad blitz to get Medicare to change its Aduhelm rul­ing: 'Dead wrong'

4 days ago
Pharma

Emer­gent TV ads book­end its tu­mul­tuous year. Can mil­i­tary, Nar­can work help re­hab its brand?

6 days ago
Pharma
latest in Marketing

Phar­ma reps need to bone up on sci­en­tif­ic da­ta and re­al-world ev­i­dence for on­col­o­gy dis­cus­sions: study

3 hours ago
Pharma

Months af­ter pulling on­ly drug from US, On­copep­tides takes back with­draw­al re­quest — but stays mum on why

Yesterday
FDA+

Pub­li­cis Health snaps up R&D mar­ket­ing group track­ing re­al-world clin­i­cal tri­als – and pa­tient sen­ti­ment

5 days ago
Pharma

Mer­ck com­mer­cial chief Frank Clyburn de­parts for CEO role at DuPont co-owned ad­di­tives com­pa­ny

5 days ago
Pharma

Q&A: Bio­Marin com­mer­cial chief Jeff Ajer gears up for biggest drug launch to date — with an­oth­er wait­ing in the wings

Last week
Pharma
see latest stories

FDA+ channel feed

6 hours ago

FDA slams Eli Lil­ly's 'mis­lead­ing' In­sta­gram ad for its type 2 di­a­betes in­jec­tion

In a first for 2022, the FDA's Of­fice of Pre­scrip­tion Drug Pro­mo­tion has is­sued an un­ti­tled let­ter, which was re­cent­ly sent to Eli Lil­ly over what the agency calls a "mis­lead­ing" and ...

READ MORE

US re­stricts use of two mon­o­clon­al an­ti­bod­ies that don't work against Omi­cron

9 hours ago

Time lim­its on ac­cel­er­at­ed ap­provals? FDA's on­col­o­gy chief Rick Paz­dur eyes po­ten­tial re­forms via in­ter­na­tion­al ...

4 days ago
latest in FDA+

Small biotech Viking slapped with clin­i­cal hold af­ter FDA says its PhIb tri­al is ac­tu­al­ly PhII

Yesterday

Flori­da man con­vict­ed of fal­si­fy­ing clin­i­cal tri­al re­sults sen­tenced to over 2 years in prison

4 days ago
Outsourcing

FDA lifts par­tial hold on Ku­ra's Phase Ib AML pro­gram as biotech re­dou­bles mit­i­ga­tion ef­forts

4 days ago

Califf on ac­cel­er­at­ed ap­provals: Com­pa­nies need to do more work be­fore FDA says OK

5 days ago

Gilead says a net­work of sup­pli­ers and dis­trib­u­tors sold tens of thou­sands of fake ver­sions of its HIV meds

6 days ago
Pharma
see latest stories

Manufacturing channel feed

Yesterday

FDA's do­mes­tic in­spec­tion hold will con­tin­ue un­til Feb­ru­ary

Amid a back­log of in­spec­tions, the FDA has an­nounced that it will ex­tend its pause of do­mes­tic in­spec­tions not con­sid­ered mis­sion-crit­i­cal due to the out­break of the Omi­cron vari­ant.

READ MORE

A Sen­ate bill wants to even an 'un­lev­el play­ing field' for do­mes­tic, for­eign in­spec­tion drop-ins amid back­log

5 days ago

Man­u­fac­tur­ing woes con­tin­ue for Au­robindo af­ter FDA's warn­ing let­ter

5 days ago
latest in Manufacturing

Re­call re­port: Miss­ing la­bel, mi­cro­bial con­t­a­m­i­na­tion leads to re­call of two batch­es of two drugs

5 days ago

Covid-19 man­u­fac­tur­ing roundup: New pro­duc­tion site opens in Africa; Sen­a­tor calls for test prices to be slashed

5 days ago

Johns Hop­kins and lo­cal biotech team up for new man­u­fac­tur­ing site; New oral drug plat­form to help ac­cel­er­ate R&D time­line

5 days ago

Fol­low­ing CRL, Re­vance says it's clear on in­struc­tions for re­sub­mit­ting BLA

5 days ago

A George Church spin­out fight­ing the vi­ral vec­tor bot­tle­neck in cell and gene ther­a­py lands $55M

6 days ago
Financing
see latest stories